Shareholders of Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) voted on July 30 to add 200,000 shares to the company's 2019 Omnibus Incentive Plan, giving the Vero Beach, Florida-based drugmaker more runway for equity-linked pay. The case for the expansion cleared the ballot. What complicates that reading is the margin: 152,958 shares were cast against the proposal versus 579,877 in favor, with 825,288 broker non-votes sitting outside the count entirely.
The equity pool vote and what the numbers say
The amendment passed at the company's 2026 Annual Meeting of Shareholders, held in person and by proxy with a quorum drawn from holders as of the June 1, 2026 record date. Abstentions on the plan totaled 2,700, a small figure relative to the outright opposition. Together the against votes and abstentions represent a real share of the ballots actually cast, and in a register where broker non-votes do not count toward the tally, that fraction carries weight.
The advisory vote on named executive officer compensation followed a similar pattern: 640,726 in favor, 89,886 against, and 4,923 abstentions. The read-through from both votes is consistent. A portion of engaged shareholders is watching how equity gets allocated, not merely whether the plan exists.
Director elections and the broker non-vote overhang
All six nominees were seated. Justin Yorke led the ballot with 710,505 votes in favor and 25,030 abstentions. Dr. David Young drew the narrowest margin: 698,511 in favor and 37,024 abstentions. The other four directors, George Ng, Khoso Baluch, James Neal, and Geraldine Pannu, fell between those poles. Each director contest carried the same 825,288 broker non-votes, a structural feature of the meeting that kept institutional participation off the scorecard for every contested item.
The counterargument: approval is approval
The counterargument, and it deserves its paragraph, is that Processa got what it asked for. The incentive plan passed. Executive pay was affirmed. The opposition on equity was a minority position, and proxy votes at a small-cap pharmaceutical company routinely show this kind of split. Nothing in the filing suggests the board is reading the 152,958 against votes as a mandate for change.
Auditor ratification and the filing signature
Cherry Bekaert, LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The auditor vote attracted the broadest support of any proposal: 1,541,664 in favor, 12,770 against, and 6,389 abstentions, with no broker non-votes withheld. Russell Skibsted, Chief Financial Officer, signed the 8-K on August 4, 2026.
On balance, the meeting closed cleanly. Directors are seated, Cherry Bekaert holds the audit mandate, and the incentive plan is now authorized for 200,000 additional shares. The line to watch is how management deploys that pool and whether the 152,958 dissenting votes harden into a louder signal at the 2027 meeting.